Alnylam Pharmaceuticals and Collaborators at Harvard Medical School Demonstrate In Vivo Silencing of Key Genes Implicated in the Transmission of Herpes Simplex Virus-2 (HSV-2)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of new data in the journal Cell Host & Microbe demonstrating that topical administration of an RNAi therapeutic resulted in robust and durable protection from the transmission of the herpes simplex virus-2 (HSV-2) in mice. The work is the result of an ongoing collaboration between Alnylam and the lab of Judy Lieberman, M.D., Ph.D., Senior Investigator of the Immune Disease Institute and Professor of Pediatrics, Harvard Medical School, and is supported in part by a grant from the National Institutes of Health (AI070302).

MORE ON THIS TOPIC